CRANFORD, N.J., March 23, 2021 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a
specialty pharmaceutical company developing and commercializing
critical care drug products, will participate in the virtual
Benzinga Biotech Small Cap Conference being held March 24-25, 2021. Citius Executive
Chairman, Leonard Mazur, will
present on Thursday, March 25 at
2:55 pm ET. Investors may register
for the conference at the event website.
During the corporate presentation, Mr. Mazur will discuss the
Company's Phase 3 program for its lead product candidate Mino-Lok®,
an antibiotic lock solution being developed to treat patients with
catheter-related bloodstream infections (CRBSIs).
"We are eagerly awaiting the third interim efficacy analysis
from our independent Drug Monitoring Committee regarding the
Mino-Lok® Phase 3 trial in progress," said Mr. Mazur. "This pivotal
trial is progressing according to plan, and we expect full
enrollment this year. The antibiotic lock solution market is large
and substantially underserved, with an estimated market opportunity
of $750 million in the U.S. and over
$1.5 billion worldwide."
Citius issued its most recent Letter to Shareholders in
February, highlighting recent updates on its business and clinical
developments as well as news for its pipeline of products. To read
the letter please visit the Company's Investor Info website at
ir.citiuspharma.com.
About Citius Pharmaceuticals, Inc.
Citius is a
late-stage specialty pharmaceutical company dedicated to the
development and commercialization of critical care products, with a
focus on anti-infectives and cancer care. For more information,
please visit www.citiuspharma.com.
Safe Harbor
This press release may contain
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements are made based on our
expectations and beliefs concerning future events impacting Citius.
You can identify these statements by the fact that they use words
such as "will," "anticipate," "estimate," "expect," "plan,"
"should," and "may" and other words and terms of similar meaning or
use of future dates. Forward-looking statements are based on
management's current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock price. Factors that
could cause actual results to differ materially from those
currently anticipated are: our ability to successfully undertake
and complete clinical trials and the results from those trials for
our product candidates, including Mino-Lok®; the estimated markets
for our product candidates and the acceptance thereof by any
market; our need for substantial additional funds; risks relating
to the results of research and development activities;
uncertainties relating to preclinical and clinical testing; the
early stage of products under development; market and other
conditions; risks related to our growth strategy; patent and
intellectual property matters; our ability to attract, integrate,
and retain key personnel; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships; our
ability to identify, acquire, close and integrate product
candidates and companies successfully and on a timely basis; our
dependence on third-party suppliers; government regulation;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
Contact:
Andrew
Scott
Vice President, Special Projects
(O) 908-967-6677 x105
(M) 646-522-8410
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-highlight-its-phase-3-clinical-trial-product-mino-lok-at-benzinga-biotech-small-cap-conference-on-march-25-301253709.html
SOURCE Citius Pharmaceuticals, Inc.